- Free from Publisher VG Athyros, AA Papageorgiou, VV Athyrou, … - Diabetes Care, 2002 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—A total of 120 consecutive patients, who were free
of coronary artery disease (CAD) at entry, were studied for a period of 24
weeks. These patients were randomly assigned to atorvastatin (20 mg/day, n ... Cited by 175 - Related articles - BL Direct - All 8 versions
GL Vega, PTS Ma, NB Cater, N Filipchuk, S … - The American journal of cardiology, 2003 - Elsevier Combined hyperlipidemia predisposes subjects to coronary heart disease. Two
lipid abnormalities—increased cholesterol and atherogenic dyslipidemia—are
potential targets of lipid-lowering therapy. Successful management of both ... Cited by 119 - Related articles - All 4 versions
SM Grundy, GL Vega, Z Yuan, WP Battisti, WE … - The American journal of cardiology, 2005 - Elsevier Patients with combined hyperlipidemia (elevated triglyceride [TG] levels,
elevated low-density lipoprotein [LDL] cholesterol, and multiple lipoprotein
abnormalities) are at increased risk for coronary heart disease. We ... Cited by 151 - Related articles - All 8 versions
PN Durrington, J Tuomilehto, A Hamann, D … - Diabetes research and clinical practice, 2004 - Elsevier The aim of this study was to evaluate the effects of rosuvastatin and
fenofibrate alone and in combination in type 2 diabetes associated with combined
hyperlipidaemia. A total of 216 patients with total cholesterol ≥200 ... Cited by 68 - Related articles - All 8 versions
… , TP Didangelos, MV Carina, DF Kranitsas, … - The American journal of cardiology, 1997 - Elsevier No monotherapy is able to tackle effectively all atherogenic features of
familial combined hyperlipidemia: high low-density lipoprotein (LDL)
cholesterol, triglycerides (TG), and plasma fibrinogen, as well as low high- ... Cited by 140 - Related articles - BL Direct - All 6 versions
G Derosa, AEG Cicero, G Bertone, MN Piccinni … - Clinical therapeutics, 2004 - Elsevier This 12-month, randomized, double-blind, controlled trial was conducted at the
University of Pavia, Pavia, Italy. Patients aged 18 to 80 years with combined
hyperlipidemia, type 2 DM, and CHD were randomly assigned to receive ... Cited by 43 - Related articles - All 4 versions
HB Rubins, SJ Robins, D Collins, DB Nelson, … - Archives of Internal Medicine, 2002 - archinte.highwire.org You are seeing this message because your Web browser does not support basic Web
standards. Find out more about why this message is appearing and what you can do
to make your experience on this site better. ... Add to CiteULike Add to ... Cited by 449 - Related articles - BL Direct - All 5 versions
E BSc, LB Ruth, MD McPherson… - The American journal of cardiology, 1998 - Elsevier To assess the long-term efficacy and use of fenofibrate together with a
3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor
(“statin”) in the treatment of elevated levels of triglycerides and low- ... Cited by 138 - Related articles - BL Direct - All 4 versions
PH Jones, MH Davidson - The American journal of cardiology, 2005 - Elsevier There is an increasing trend among physicians to use 3-hydroxy-3-methylglutaryl
coenzyme A reductase inhibitors (statins) in combination with other
antilipidemic agents. The complementary lipid-altering effects of statins ... Cited by 197 - Related articles - All 12 versions
ML Kashyap, ME McGovern, K Berra, JR … - The American journal of cardiology, 2002 - Elsevier Combination therapy is increasingly recommended for patients with multiple lipid
disorders, especially those at high risk for coronary events. We investigated
the long-term safety and effectiveness of a new drug formulation containing ... Cited by 228 - Related articles - BL Direct - All 8 versions
